The Europe Medicines Agency has rejected Merck Serono’s new multiple sclerosis treatment Movectro, saying its benefits do not outweigh its …
Amphista doses first patient in AML trial of protein degrader
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand

